Occam has placed Matt Gall as CFO of iTeos, an MPM-backed immuno-oncology company that has raised over $200M in financing from marquee investors including RA Capital, Boxer, and Janus. Gall joins at an exciting phase in the company’s development as multiple programs enter into the clinic.
Gall joins iTeos Therapeutics from Sarepta Therapeutics, Inc. where he was the Senior Vice President of Corporate Development and Treasurer. At Sarepta, Matthew led the Company’s recent multibillion partnership deal with Roche, and during his tenure, he oversaw the Company’s financial strategy and helped raise over $2 billion in capital. During his 15-year career in biotech, Matthew also worked at Celgene Corporation and Gilead Sciences in various roles including financial management and business development. Matthew holds an MBA from the University of Chicago Booth School of Business.